These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35813758)

  • 21. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma.
    Shimizu K; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
    Cancer Manag Res; 2017; 9():741-750. PubMed ID: 29238224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
    Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.
    Lopci E; Toschi L; Grizzi F; Rahal D; Olivari L; Castino GF; Marchetti S; Cortese N; Qehajaj D; Pistillo D; Alloisio M; Roncalli M; Allavena P; Santoro A; Marchesi F; Chiti A
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1954-61. PubMed ID: 27251642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy.
    Wei Z; Zhan X; Fan L; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Meng M; Ni Y; Li Q
    Int J Hyperthermia; 2018; 35(1):591-598. PubMed ID: 30307348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Significance of Tumor Immunity in Surgically Resected Pulmonary Pleomorphic Carcinoma.
    Kaira K; Shimizu K; Endoh H; Imaizumi K; Kamiyoshihara M; Sugano M; Kawashima O; Tanaka S; Fujita A; Imai H; Kogure Y; Oyama T; Asao T; Shirabe K
    Anticancer Res; 2020 Jan; 40(1):261-269. PubMed ID: 31892575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer.
    Ahn H; Lee HJ; Lee JH; Cho HD; Oh MH; Son JW; Jang SH
    Pathol Res Pract; 2020 Nov; 216(11):153188. PubMed ID: 32919305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy.
    Ou D; Adam J; Garberis I; Blanchard P; Nguyen F; Levy A; Casiraghi O; Gorphe P; Breuskin I; Janot F; Temam S; Scoazec JY; Deutsch E; Tao Y
    Oncoimmunology; 2017; 6(9):e1341030. PubMed ID: 28932643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic and Therapeutic Implications of Immune Classification by CD8
    García-Marín R; Reda S; Riobello C; Cabal VN; Suárez-Fernández L; Vivanco B; Álvarez-Marcos C; López F; Llorente JL; Hermsen MA
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and prognostic value of PD-L1 in non-schistosoma-associated urinary bladder squamous cell carcinoma.
    Liu Z; Meng Y; Cao Y; Chen Y; Fan Y; Li S; He Q; Wu S; Yu W; Jin J
    Transl Androl Urol; 2020 Apr; 9(2):428-436. PubMed ID: 32420148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma.
    Kim R; Coppola D; Wang E; Chang YD; Kim Y; Anaya D; Kim DW
    Oncotarget; 2018 May; 9(34):23366-23372. PubMed ID: 29805739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.
    He Y; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Yu H; Zhou C; Hirsch FR
    Med Sci Monit; 2017 Mar; 23():1208-1216. PubMed ID: 28275222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer.
    Kesar N; Winkelmann R; Oppermann J; Ghanaati S; Martin D; Neumayer T; Balster S; Rödel C; Rödel F; von der Grün J; Balermpas P
    Oral Oncol; 2020 Dec; 111():104931. PubMed ID: 32736208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma.
    Wuerdemann N; Gültekin SE; Pütz K; Wittekindt C; Huebbers CU; Sharma SJ; Eckel H; Schubotz AB; Gattenlöhner S; Büttner R; Speel EJ; Klussmann JP; Wagner S; Quaas A
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma.
    Gachechiladze M; Škarda J; Skanderová D; Überall I; Kolek V; Smičkova P; Vojta P; Vbrková J; Hajdúch M; Shani I; Kolář Z; Stahel R; Weder W; Rulle U; Soltermann A; Joerger M
    Lung Cancer; 2020 Sep; 147():30-38. PubMed ID: 32653671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression and Prognostic Value of Tumor-Infiltrating Lymphocytes and PD-L1 in Hepatocellular Carcinoma.
    Nie H; He T; Wang L; Zhang L
    Onco Targets Ther; 2021; 14():1377-1385. PubMed ID: 33658801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
    Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.